Qiagen NV
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
150 / 240
Position in country
189 / 223
Return on Assets, %
5.5
-2.7
Net income margin, %
19.1
-6.7
EBITDA margin, %
33.9
5.6
Debt to Equity, %
39.6
15.1
Intangible assets and goodwill, %
49
4.7
Revenue CAGR 3Y, %
1.6
12.8
Total Equity change 1Y, %
9.8
-2.4
Revenue Y, % chg
-8.3
0
P/E
26.3
32.1
P/BV
2.3
2
P/S
4.5
4.1
EV/S
4.7
3.6
EV/EBITDA
14.3
7.8
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
24.4
48.9
Forward P/E
18.5
25.5
Expected dividend per share
0
0
Payout Ratio, %
0
10.1
Dividend Ex Date
2024-01-30
Competitors
Ranks
-
Lonza Group AG
00%
-
Samsung Biologics Co Ltd
00%
-
IQVIA Holdings Inc
00%
-
West Pharmaceutical Services Inc
00%
-
Agilent Technologies Inc
00%
-
Thermo Fisher Scientific Inc
00%
-
Danaher Corp
00%
-
Qiagen NV
00%
-
Mettler-Toledo International Inc
00%
-
Sartorius Stedim Biotech SA
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Netherlands
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Life Sciences Tools & Services
Sub-sector
Health Care
Capitalization (millions of $)
8894.1
Ticker
QGEN.K
ISIN
NL0015001WM6
IPO date
1996-09-01
Availability on Russian exchanges
Yes
Reporting for
2024-03-11
Date fact. publication of reports
2023-12-31
Company Description
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: